Bunge Global SA
F:Q23
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bunge Global SA
F:Q23
|
US |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
US |
|
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
JP |
|
Seagate Technology Holdings PLC
NASDAQ:STX
|
IE |
Wall St Price Targets
Q23 Price Targets Summary
Bunge Global SA
According to Wall Street analysts, the average 1-year price target for Q23 is 120.89 EUR with a low forecast of 99.75 EUR and a high forecast of 134.09 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Q23's stock price target?
Price Target
120.89
EUR
According to Wall Street analysts, the average 1-year price target for Q23 is 120.89 EUR with a low forecast of 99.75 EUR and a high forecast of 134.09 EUR.
What is the Revenue forecast for Bunge Global SA?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 11%.
What is the Operating Income forecast for Bunge Global SA?
Projected CAGR
30%
Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 3 years is 30%.
What is the Net Income forecast for Bunge Global SA?
Projected CAGR
38%
Over the last 13 years, the compound annual growth rate for Net Income has been 30%. The projected CAGR for the next 3 years is 38%.
